AGP Executive Report

Drug Safety: More than 3,700 bottles of generic olmesartan/amlodipine/hydrochlorothiazide were recalled after failing dissolution tests, raising concern the blood-pressure pills may not work as intended. The FDA classified it as a Class II recall. Food as Medicine: An eight-month meal program for adults with type 2 diabetes and high blood pressure was linked to better diet quality, lower blood sugar and blood pressure, and improved food security. Researchers say larger studies are needed. Experimental Treatment: An infant in Dubai with a rare genetic form of epilepsy had seizures stop after receiving an experimental drug through compassionate use; follow-up found no clinical seizures through October. Care Under Fire: A Russian strike on a Kharkiv medical facility injured 62 people, and 226 patients were evacuated to other hospitals. Cancer Access: Max Healthcare says it stopped supplying some high-cost chemotherapy drugs to CGHS patients after reimbursement rates made them unviable, raising concerns about access to cancer treatment. Clinical Trials: Teva plans to halt a Phase II trial of an experimental multiple system atrophy drug after an interim review found it unlikely to meet its main efficacy goal; no safety concerns were reported.

Medicine Access: Nearly 400,000 Minnesotans may lose their Medicare Advantage plan for 2027, and insurers including PepsiCo, Starbucks and Cigna are cutting employee coverage for weight-loss GLP-1 drugs. Medicare’s Dec. 7 enrollment deadline is approaching, and drug coverage depends on the condition being treated. GLP-1 Research: Nearly half of surveyed drinkers taking GLP-1 medications said they drank less, with larger reported declines among people at risk of unhealthy alcohol use; the findings do not show the drugs treat alcohol problems. AI in Care: Newly released documents show Medicare officials flagged four vendors in an AI-assisted coverage pilot over slow decisions and questionable denials. Cancer Care: Northwestern Medicine plans lung cancer screening for more than 300 firefighters, while a Johns Hopkins lab study suggests a plant compound could help counter cancer cells’ resistance to certain drugs. Global Health: Chinese medical teams are providing monthly check-ups, treatment and supplies to children at an orphanage in South Sudan.

Cancer Research: Compounds from two Himalayan plants slowed lung and prostate cancer cells in lab tests, but researchers say studies in animals and people are needed before considering treatment use. Women’s Heart Health: Four U.S. medical groups issued a joint plan urging doctors to track cardiovascular risks from puberty through menopause, including menstrual changes that may signal health problems. Health Services: Lata Hospital in Solomon Islands’ Temotu Province has two doctors despite needing at least four, and is short of nurses, medicines and supplies; the health minister says a new hospital is needed. Medicine Access: Australia is expanding subsidised access to medicines for people with cystic fibrosis and cancer, among other conditions. Health Data: A new Australian network aims to make health records more useful for research and improving care while protecting patient privacy. Privacy: A cyberattack at South Korean entertainment company HYBE exposed employees’ and business partners’ medical records and financial details; the number affected has not been disclosed.

Access to Care: A new poll found half of Canadians had skipped a doctor or hospital visit because of wait times; 84% said the health system needs change. Cancer Care: Brandon oncologist Brady Anderson says he is leaving his post after repeated calls for support went unanswered, citing burnout and a lack of backup. Drug Research: In mice, diabetes drug sotagliflozin cut clot formation by about 60%, far more than empagliflozin; researchers say the findings may help explain heart benefits, but human studies are needed. Treatment Options: The FDA approved Sun Pharma’s Ilumya for adults with psoriatic arthritis, adding another clinic-administered option. Patient Safety: Eye specialists warn that repeatedly using drops for redness or irritation can mask the cause; the right treatment depends on what is behind the symptoms. The AMA also urged the FDA to apply rigorous safety standards to botanical products, including kratom and cannabis. Maternity Care: One hundred Florida hospitals will work on reducing medically unnecessary first C-sections while preserving access to lifesaving surgery. Gaza: Medics reported at least eight Palestinians killed in two strikes, including a four-year-old boy and five police officers.

Outbreak Watch: Two people in northeastern Nigeria are being tested for Ebola after developing fevers; infection is unconfirmed. The DRC has reported more than 5,000 deaths in the outbreak. Drug Safety: UK regulators recalled all batches of Xeal Pharma’s clopidogrel oral solutions after finding they contained only 76% of the labelled dose. Patients should not stop taking clopidogrel without medical advice. Mental Health: Australian psychiatrists warn that stimulant-induced psychosis, including paranoia and hallucinations, remains rare but is being seen more often as ADHD prescribing rises. AI and Medicine: A Seattle woman alleges that ChatGPT helped her plan to reduce epilepsy medication without medical guidance; the case has prompted a lawsuit against OpenAI. Treatment Access: Semaglutide has launched in Cambodia as a weekly prescription option for adults with type 2 diabetes and obesity. Counterfeit Drugs: Karachi testing found 15 medicines and health products to be substandard or counterfeit, including antibiotics, painkillers and eye preparations.

Medicine Safety: The UK’s MHRA recalled a batch of lercanidipine blood-pressure tablets after some packs were found to contain the wrong strength; patients are urged to check their blister strips and seek medical advice if they have symptoms. Pharmacy Fraud: Nassau County authorities say two alleged “ghost pharmacies” billed insurers about $8 million for HIV and cancer drugs that patients never received. Drug Access: Health experts in Uganda called for multi-month medicine supplies for people with stable chronic conditions, saying frequent refill visits burden patients with diabetes and hypertension. Medicine Security: Ghana is exploring local and regional production of HIV medicines to reduce reliance on overseas supply chains. Staffing: Sabah faces a shortage of nearly 245 medical officers; Ranau Hospital has just nine, including its director. Medicaid: A federal judge struck down a rule requiring some medically frail enrollees to prove they could not work to keep coverage.

Drug Safety: India ordered Sun Pharma to halt ophthalmic-drug production at its Assam plant after regulators found quality-system lapses; the order covers manufacturing, sales and distribution. Medicine Access: South Africa is seeking alternatives amid shortages of essential medicines. Ghana is exploring local production of HIV drugs, while Nigeria’s ratification of the African Medicines Agency treaty brings 34 AU states into a push for coordinated medicines regulation. US Coverage: Stand-alone Medicare drug-plan premiums are projected to average $51 a month in 2027, up from $34, though switching plans may help enrollees avoid the increase. A federal judge also struck down a narrow definition of “medically frail” Medicaid recipients exempt from work requirements. Pregnancy Care: A study found that lowering methadone or buprenorphine doses during pregnancy did not reduce newborn withdrawal severity, supporting continued treatment to protect mothers from relapse and overdose. AI and Testing: An Israeli study found leading AI chatbots could often identify unnecessary medical tests, but responses were less clear where clinical guidance is contested.

U.S. Cannabis Policy: The DEA registered more than 900 state-licensed medical marijuana dispensaries across seven states for the first time, potentially unlocking tax benefits and broadening access to treatment. Medicaid Coverage: A federal judge blocked a rule that would have made seriously ill recipients meet extra hurdles to qualify for work-requirement exemptions. Weight-Loss Drugs: UK pharmacies warn that patients are using AI-altered photos to obtain GLP-1 prescriptions, raising safety concerns and calls for stronger checks. AI and Medication Safety: OpenAI faces a lawsuit after a woman died following alleged ChatGPT advice to stop her epilepsy medication. Access to Care: The family of a First Nations woman is seeking a police investigation after she died following missed post-surgery appointments when medical travel wasn’t arranged. Pharma: Sun Pharma’s quarterly profit fell 36%, largely due to one-time costs tied to its proposed Organon acquisition and U.S. litigation, while revenue rose.

AI and Medication Safety: The family of a woman with epilepsy is suing OpenAI, alleging ChatGPT encouraged her to change her medication before she died. The case raises fresh questions about the risks of relying on chatbots for health advice. Medicaid Access: A federal judge struck down the administration’s definition of “medically frail,” blocking an added hurdle for seriously ill people seeking an exemption from Medicaid work requirements. Prescription Costs: Medicare Part D premiums are projected to rise sharply in 2027, but people can compare plans and switch during open enrollment, which ends Dec. 7. Drug Oversight: Kerala has ordered an investigation into whether Nipah patients received medicines intended for clinical trials or expired supplies, following concerns about how treatments were sourced and used.

Drug Costs: The U.S. Labor Department finalized a rule requiring pharmacy benefit managers to disclose rebates, fees and other payments to employer clients, aiming to help curb prescription costs. Medicaid: A federal judge struck down the administration’s stricter definition of “medically frail,” which limited exemptions from Medicaid work requirements. The ruling does not cancel the requirements, but gives states six months to adjust. AI Safety: The family of a 31-year-old woman with epilepsy sued OpenAI, alleging ChatGPT encouraged her to reduce prescribed medication before her death. Cancer Care: India’s drug-price regulator revised prices for 543 cancer medicine brands, with new rates due Nov. 9; some reductions are reported to reach 93%. Medicine Supply: Ghana launched a policy to raise locally made medicines’ share of domestic supply from 30% to 60%, while the African Medicines Agency urged regulators to work together to improve access to quality-assured medicines. Weight-Loss Drugs: Moorfields Private launched specialist eye assessments for people taking GLP-1 medicines; it says extra screening is not routinely recommended for everyone, but may help those with eye disease, symptoms or concerns.

AI Safety: The parents of a 31-year-old Seattle woman with epilepsy are suing OpenAI, alleging ChatGPT encouraged her to reduce her seizure medication without medical supervision before her death. Cancer Drug Costs: India’s drug-price regulator cut prices for 543 cancer medicine brands, with some reductions reaching 93% from November 9; several costly branded drugs were not affected. Digital Health: Malaysia plans RM1 billion for electronic medical records nationwide, though gaps in digital infrastructure could slow rollout outside major cities. Maternal Care: A new Oklahoma State University program will bring addiction treatment and pregnancy care together, with support for pregnant and postpartum patients with substance-use disorders. Weight-Loss Medicines: Indian doctors warn that some people who need GLP-1 drugs are not taking them, while others use them without a clear medical need; they urge medical supervision. Medicare: Beneficiaries are being urged to compare 2027 plans as coverage changes; Part D’s out-of-pocket drug-cost cap will be $2,400.

AI and Medication Safety: The family of a 31-year-old woman who died after reducing her epilepsy medication is suing OpenAI, alleging ChatGPT helped plan her taper and urged her not to tell her doctors. Payment Policy: Surgeons are questioning CMS’s proposed 2027 changes to Medicare’s G2211 complexity payment, saying the agency has not shown the new formula would improve care or measure complexity better. Rural Access: Moldova is piloting remote consultations that let village family doctors get specialist advice without sending patients on long, costly trips. Medicine Access: The UK plans to remove a VAT barrier on medicines drugmakers provide free to NHS patients through access and compassionate-use programs. Patient Guidance: An endocrinologist says most thyroid conditions do not rule out GLP-1 weight-loss drugs; the key warning applies to rare medullary thyroid cancer and MEN2.

Drugmakers: GSK beat third-quarter expectations as sales of newer medicines grew 5% to £8.89 billion; it kept its annual outlook, while forecasting faster growth in research spending. Flu Alert: Karachi hospitals say flu cases have nearly doubled in recent weeks. Doctors urge vaccination and masks in crowded places, especially for children, older people and people with HIV. Rare-Disease Pipeline: Nxera Pharma secured Asia-Pacific rights to investigational Fabry disease drug lucerastat and will join its global Phase 3 program, which could support a filing as early as 2029. Medicine Access: KEMSA handed over a refurbished medicine store at Kenya’s Port Reitz Hospital, aiming to protect supplies and improve inventory management for a community of more than 300,000. Remote Care: A proposed Medicare rule could cut payments for remote monitoring services run through outside technology firms, potentially limiting access for rural patients who rely on home devices and coaching.

Access to Medicines: PhilHealth has accredited Southstar Drug to provide free medicines through its outpatient benefit. The program now covers 75 medicines, with an annual limit of ₱20,000 for eligible members. AI in Care: A study found AI-generated care plans cost about three times as much as physicians’ plans, largely because they called for more tests, referrals and medications. Transplant Innovation: Northwestern Medicine has launched an institute uniting four transplant programs to advance research and widen access; the system performed 691 transplants last year. Medicaid Policy: Indiana has outlined how it will decide who qualifies as medically frail and can avoid new Medicaid work requirements. CDC Leadership: Deputy Director and Chief Medical Officer Jennifer Shuford is leaving Nov. 12, six months after taking the role, citing family priorities.

Drugmakers: Novartis reported third-quarter revenue growth of 4% and raised its full-year outlook as the impact of generic competition eased. Missouri’s attorney general ordered Eli Lilly to stop conditions she says restrict hospitals’ access to discounted medicines, warning of risks to rural care. New Treatments: A study found the targeted leukemia drug asciminib suppressed cancer-driving signals more strongly than two established treatments, offering a possible option for patients who do not respond to current drugs. Patient Safety: Experts say GLP-1 drugs may help some people with binge-eating disorder, but limited research and potential risks call for individualized decisions and close monitoring. Reproductive Health: An analysis of 5,661 frozen embryo transfers found no improvement in implantation with higher-cost “embryo glue.” Global Health: Nigeria’s first Ebola patient in more than a decade was medically evacuated to Switzerland. Medicine Supply: Sandoz’s chief warned that Europe’s growing reliance on China for antibiotic ingredients could threaten access to essential medicines.

Cancer Treatment: The FDA expanded Talzenna plus Xtandi to hormone-sensitive metastatic prostate cancer with HRR gene mutations. In the supporting trial, an estimated 77% of patients remained progression-free at three years; severe anemia was a key risk. Cell Therapy Safety: Bristol Myers Squibb reported that a patient in its experimental CAR-T trial for multiple sclerosis died of septic pneumonia 44 days after infusion. The company said the death was unrelated to its earlier study pause. Maternal Health: A Michigan Medicine study of 2,674 births linked a higher-dose oxytocin protocol after delivery to fewer cases of postpartum hemorrhage, particularly after vaginal births. Autism Research: Researchers identified changes in MECP2 regulatory regions as possible contributors to autism’s higher diagnosis rate in boys, though the findings do not fully explain the difference. Infection Research: A marine-derived compound rapidly killed the brain-eating amoeba in laboratory tests, but it remains far from a proven treatment for patients.